Stocks › HRTX
HERON THERAPEUTICS, INC. /DE/
HRTX·Nasdaq·
United States·USD
United States·USD$0.33
-0.04 (-10.35%)
Close · Oct 6, 2026 · Close Prices from Tiingo.com
HRTX
HERON THERAPEUTICS, INC. /DE/ · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
HRTXS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of HRTX by members of U.S. Congress · 1 on record
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
 Ashley HinsonHouse · R · IA |
HRTXHERON THERAPEUTICS, INC. /DE/ · Stock |
Sale $1,001 - $15,000 |
Apr 5, 2021 | Mar 31, 2021 | Filing ↗ |
Whale Activity
Position changes in HRTX reported for 2026-06-30 by 8 tracked institutional filers
- Increased2
- New0
- Held0
- Decreased5
- Closed1
- No prior filing0
| Filer | Shares | Value | Change |
|---|---|---|---|
| BlackRock, Inc. | 10.6M | $4.5M | increased |
| VANGUARD CAPITAL MANAGEMENT LLC | 7.8M | $3.3M | decreased |
| MILLENNIUM MANAGEMENT LLC | 4.1M | $1.7M | decreased |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1.6M | $675K | increased |
| RENAISSANCE TECHNOLOGIES LLC | 1.5M | $643K | decreased |
| TWO SIGMA INVESTMENTS, LP | 266.3K | $114K | decreased |
| D. E. Shaw & Co., Inc. | 120.4K | $51K | decreased |
| Citadel Advisors LLC | 0 | $0 | closed |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Net shares bought (+) or sold (−) on the open market by HRTX insiders, by quarter · Form 4
No open-market insider buys or sells in the last two years.
Recent Insider Transactions
437 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Duarte IraEVP, Chief Financial Officer | Tax withholding | −3,555 | $0.38 | $1K | Jun 16, 2026 | Form 4 ↗ |
| Duarte IraEVP, Chief Financial Officer | Option exercise | +12.5K | — | — | Jun 16, 2026 | Form 4 ↗ |
| Forbes William PEVP, Chief Development Officer | Option exercise | +12.5K | — | — | Jun 6, 2026 | Form 4 ↗ |
| Hensley Mark EarlChief Operating Officer | Option exercise | +125.0K | — | — | May 6, 2026 | Form 4 ↗ |
| Hensley Mark EarlChief Operating Officer | Option exercise | +11.8K | — | — | Apr 30, 2026 | Form 4 ↗ |
| Forbes William PEVP, Chief Development Officer | Option exercise | +11.8K | — | — | Apr 30, 2026 | Form 4 ↗ |
| Forbes William PEVP, Chief Development Officer | Option exercise | +11.7K | — | — | Apr 30, 2026 | Form 4 ↗ |
| Duarte IraEVP, Chief Financial Officer | Option exercise | +13.5K | — | — | Apr 30, 2026 | Form 4 ↗ |
| Duarte IraEVP, Chief Financial Officer | Option exercise | +11.7K | — | — | Apr 30, 2026 | Form 4 ↗ |
| Collard Craig AChief Executive Officer · Director | Option exercise | +50.0K | — | — | Apr 30, 2026 | Form 4 ↗ |
| Collard Craig AChief Executive Officer · Director | Option exercise | +34.8K | — | — | Apr 30, 2026 | Form 4 ↗ |
| Forbes William PEVP, Chief Development Officer | Option exercise | +3,874 | — | — | Apr 19, 2026 | Form 4 ↗ |
| Collard Craig AChief Executive Officer · Director | Option exercise | +13.8K | — | — | Apr 19, 2026 | Form 4 ↗ |
| Duarte IraEVP, Chief Financial Officer | Option exercise | +3,874 | — | — | Apr 19, 2026 | Form 4 ↗ |
| Collard Craig AChief Executive Officer · Director | Option exercise | +62.5K | — | — | Apr 3, 2026 | Form 4 ↗ |
| Duarte IraEVP, Chief Financial Officer | Option exercise | +11.7K | — | — | Jan 31, 2026 | Form 4 ↗ |
| Forbes William PEVP, Chief Development Officer | Option exercise | +11.7K | — | — | Jan 31, 2026 | Form 4 ↗ |
| Collard Craig AChief Executive Officer · Director | Option exercise | +34.8K | — | — | Jan 31, 2026 | Form 4 ↗ |
| Christian WaageDirector | Grant / award | +54.0K | $0.00 | $0 | Jan 30, 2026 | Form 4 ↗ |
| Kaseta MichaelDirector | Grant / award | +54.0K | $0.00 | $0 | Jan 30, 2026 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding HRTX · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 5.5M | $2.3M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF iShares Trust | 3.7M | $1.6M | 0.00% | Jun 30, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 2.1M | $881K | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund Fidelity Salem Street Trust | 1.6M | $807K | 0.00% | Jul 31, 2026 |
| Schwab U.S. Small-Cap ETF SCHWAB STRATEGIC TRUST | 869.9K | $757K | 0.00% | May 31, 2026 |
| VANGUARD RUSSELL 2000 INDEX FUND VANGUARD SCOTTSDALE FUNDS | 784.0K | $682K | 0.00% | May 31, 2026 |
| iShares Russell 2000 Growth ETF iShares Trust | 1.4M | $581K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund Fidelity Concord Street Trust | 666.2K | $580K | 0.00% | May 31, 2026 |
| State Street Institutional Small-Cap Equity Fund STATE STREET INSTITUTIONAL FUNDS | 581.4K | $465K | 0.10% | Mar 31, 2026 |
| VANGUARD HEALTH CARE INDEX FUND VANGUARD WORLD FUND | 415.5K | $362K | 0.00% | May 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list HRTX's shares (CUSIP 427746102), each fund at its latest report since Mar 7, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming heron therapeutics as client
- FARRAGUT PARTNERS LLPHERON THERAPEUTICS, INC. · 2026 Q2 · HCR, MMM$50K
Filing ↗ - FARRAGUT PARTNERS LLPHERON THERAPEUTICS, INC. · 2026 Q1 · HCR, MMM$50K
Filing ↗ - FARRAGUT PARTNERS LLPHERON THERAPEUTICS, INC. · 2025 Q4 · HCR, MMM$50K
Filing ↗ - FARRAGUT PARTNERS LLPHERON THERAPEUTICS, INC. · 2025 Q3 · HCR, MMM$50K
Filing ↗ - FARRAGUT PARTNERS LLPHERON THERAPEUTICS, INC. · 2025 Q2 · HCR, MMM$50K
Filing ↗
Government Contracts
Federal awards to HERON THERAPEUTICS, INC. /DE/ · USAspending
No federal contract awards found for HERON THERAPEUTICS, INC. /DE/.
U.S. Patents
Recent USPTO applications naming HERON THERAPEUTICS, INC. /DE/
No USPTO patent applications found for HERON THERAPEUTICS, INC. /DE/.
Annual Financials
From HRTX's 10-K filings · XBRL
No annual XBRL figures on record for HRTX. KeyVex's fundamentals cover about 130 large companies so far.
Stock Splits
Every split and reverse split in the price history
- 1-for-20Reverse splitJan 13, 2014
- 1-for-4Reverse splitMay 25, 2007
Split dates and ratios from the price history · Close Prices from Tiingo.com
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 1.01, 9.01Material agreementSep 29, 2026
EDGAR ↗ - 8-K · Items 1.01, 3.03, 9.01Material agreement · Modification of rightsAug 14, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsAug 10, 2026
EDGAR ↗ - 8-K · Items 3.01, 9.01Delisting noticeJun 25, 2026
EDGAR ↗ - 8-K · Items 5.07Shareholder voteJun 16, 2026
EDGAR ↗ - 8-K · Items 8.01, 9.01Other eventsJun 2, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsMay 11, 2026
EDGAR ↗
About HERON THERAPEUTICS, INC. /DE/
From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersSAN DIEGO, CA
IncorporatedDE
SEC CIK0000818033 ↗
Former namesAP PHARMA INC /DE/, ADVANCED POLYMER SYSTEMS INC /DE/